REFERENCES


Ballantyne CM, Raichlen JS, Nicholls SJ, et al. (2008) ASTEROID Investigators Effect of rosvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of


Belhassen L, Pelle G, Dubois Rande JL, Adnot S (2003). Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with


Cai J et al. (2005) In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: Circulation 112: 3437–3444


Cannon CP, Husted S, Harrington RA, et al. (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-


Colhoun HM, Betteridge DJ, Durrington PN, et al. (2004) CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in
type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet;364(9435):685-696


Fiessinger JN. S18886(2004), a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. Eur Heart J. 2004;25:573.


Kraitchman DL et al. (2005) Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112: 1451–1461


Leong-Poi H et al. (2005) Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 111: 3248–3254


**MacFadyen RJ, Lee AFC, Morton JJ, et al (1999).** How often are angiotensin II concentrations and aldosterone concentrations raised during chronic ACE
inhibitor treatment in cardiac failure? Heart. 1999;82:57–61. [PMC free article] [PubMed]


**Reilly MP et al. (2005)** Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation* 111: 932–939


